BackProvectus Biopharmaceuticals Overview

Provectus Biopharmaceuticals Long Term Debt

Provectus Biopharmaceuticals's long-term debt is $54K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$53920.00
48.10% YoYΔ $-49980.00 vs prior year quarter

Peer trimmed avg / median

Loading

Provectus Biopharmaceuticals Long Term Debt History

Loading

Provectus Biopharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Provectus Biopharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Provectus Biopharmaceuticals (PVCT) FAQ

As of the most recent data (June 2026), PVCT shows a long-term debt of $54K. That compares with $100K in the prior-year period — down 48.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PVCT's long-term debt is now $54K (was $100K) — a 48.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Provectus Biopharmaceuticals is outperforming or lagging.

Tracking PVCT's long-term debt over time shows whether Provectus Biopharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $54K That compares with $100K in the prior-year period — down 48.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Provectus Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $54K) with ownership activity and broader fundamentals.

Provectus Biopharmaceuticals's long-term debt is $54K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.